Group testing for infectious disease detection

Document text

Principal Investigator: Christopher R Bilder
Organization: UNIVERSITY OF NEBRASKA LINCOLN
Fiscal Year: 2024
Award: $429,353
Funding agency: National Institute of Allergy and Infectious Diseases

Project Summary/Abstract
Testing high volumes of clinical specimens for infectious diseases requires the use of efficient testing approaches.
One approach used by laboratories is a procedure known as group testing (also known as pooled testing). In
its most basic application, portions of specimens from different people are combined together into “groups” so
that each corresponding individual is represented within one group. These groups are tested as if they were only
single specimens. Members of negative groups are declared negative. Members of positive groups are retested
separately in a second stage of testing to determine who is positive and who is negative. When group sizes are
chosen in a statistically appropriate manner, the number of people represented by negative groups is much larger
than those in positive groups. This leads to significant reductions in the overall number of tests required when
compared to testing each specimen separately. These reductions subsequently result in significant increases
for laboratory testing capacity by applying the resources saved to test more specimens. Current applications of
group testing include: 1) testing blood donations for viruses, including hepatitis B and West Nile; 2) screening for
bacteria that lead to chlamydia and gonorrhea; 3) checking for antiretroviral treatment failure among HIV-positive
individuals; and 4) testing for viruses during a pandemic, including SARS-CoV-2.
 There are different algorithmic approaches to group testing. Members of positive testing groups can be
successively split into smaller groups over two or more stages of testing. Alternatively, individual specimens can
be allocated to multiple groups during the initial stage of testing in an effort to reduce the number of subsequent
stages of testing. The first goal of this research to develop new group testing strategies that require few stages.
This will enable laboratories to more easily implement group testing and to report test results quicker. The second
goal is to develop new statistical learning methods for data arising through group testing. These methods will
result in better predictions for the probability of positivity and can be used to develop more efficient approaches
to implement group testing. The third goal is to create tools for laboratories so that they can apply this research.
These tools will include a web-based application that allows laboratories to choose the most efficient group testing
strategy for their particular situation.

Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><AIDS Virus><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome Virus><Algorithms><American><Anti-HIV Positivity><Area><Assay><Award><Bacteria><Bioassay><Biological Assay><Biometrics><Biometry><Biostatistics><Blood Donations><Blood Tests><C trachomatis><C. trachomatis><COVID assay><COVID crisis><COVID epidemic><COVID pandemic><COVID-19 assay><COVID-19 crisis><COVID-19 epidemic><COVID-19 era><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 pandemic><COVID-19 period><COVID-19 public health crisis><COVID-19 virus><COVID-19 years><COVID19 assay><COVID19 virus><Centers for Disease Control><Centers for Disease Control and Prevention><Centers for Disease Control and Prevention (U.S.)><Chlamydia><Chlamydia trachomatis><Classification><Clinical><CoV-2><CoV2><Communicable Diseases><Country><Data><Detection><Disease><Disorder><Goals><Gonococcal Infection><Gonococcus><Gonorrhea><Government Officials><Grant><HIV><HIV Positive><HIV Positivity><HIV Seroconversion><HIV Seropositivity><HIV antibody positive><HTLV-III Seroconversion><HTLV-III Seropositivity><Health Care Professional><Health Professional><Healthcare professional><Hematologic Tests><Hematological Tests><Hematology Testing><Hepatitis B><Hour><Human Immunodeficiency Viruses><Individual><Infectious Disease Pathway><Infectious Diseases><Infectious Disorder><Investigators><Journals><LAV-HTLV-III><Laboratories><Lead><Learning><Lymphadenopathy-Associated Virus><M genitalium><M. genitalium><Magazine><Measures><Medical><Methodology><Methods><Miyagawanella><Modeling><Mycoplasma genitalium><N gonorrhea><N gonorrhoeae><N. gonorrhea><N. gonorrhoeae><NIH><National Institutes of Health><Neisseria gonorrhea><Neisseria gonorrhoeae><New York><Normalcy><Normalities><Paper><Pb element><Persons><Play><Probability><Procedures><Public Health><Publishing><R-Series Research Projects><R01 Mechanism><R01 Program><Reporting><Research><Research Grants><Research Personnel><Research Project Grants><Research Projects><Research Resources><Research Specimen><Researchers><Resources><Response Latencies><Rickettsia trachomae><Role><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 assay><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 pandemic><SARS-CoV2><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Scientist><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome related corona virus 2><Sexually Transmitted Diseases><Sexually Transmitted Disorder><Sexually Transmitted Infection><Specimen><Stream><Systematics><Test Result><Testing><Time><Treatment Failure><United States Centers for Disease Control><United States Centers for Disease Control and Prevention><United States National Institutes of Health><Universities><Venereal Diseases><Venereal Disorders><Venereal Infections><Viral Hepatitis B><Virus><Virus-HIV><West Nile><Work><Wuhan coronavirus><antiretroviral therapy><antiretroviral treatment><application in practice><bedsonia><coping><coronavirus disease 2019 assay><coronavirus disease 2019 crisis><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 pandemic><coronavirus disease 2019 public health crisis><coronavirus disease 2019 virus><coronavirus disease assay><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><coronavirus disease-19 global pandemic><coronavirus disease-19 pandemic><coronavirus disease-19 virus><disease risk><disorder risk><future pandemic><hCoV19><heavy metal Pb><heavy metal lead><innovate><innovation><innovative><learning activity><learning method><learning strategies><learning strategy><member><multiplex assay><nCoV2><next pandemic><normality><online app><pandemic><pandemic disease><pathogen><practical application><response><screening><screenings><serum hepatitis><severe acute respiratory syndrome coronavirus 2 assay><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><sexually acquired infection><social role><statistical learning><therapy failure><tool><viral detection><viral testing><virus detection><virus testing><web app><web application><web based app><web based application>